Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $55,430 - $86,940
2,740 New
2,740 $59,000
Q2 2022

Aug 15, 2022

SELL
$17.91 - $52.25 $28,064 - $81,875
-1,567 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$41.58 - $80.89 $65,155 - $126,754
1,567 New
1,567 $72,000
Q3 2021

Nov 15, 2021

SELL
$46.83 - $73.5 $207,082 - $325,017
-4,422 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $165,427 - $275,269
4,422 New
4,422 $235,000
Q1 2021

May 17, 2021

SELL
$35.69 - $52.72 $11,420 - $16,870
-320 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$31.71 - $57.97 $10,147 - $18,550
320 New
320 $17,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.